Wall Street analyst estimates for IRIDEX Corporation (IRIX): consensus price target, buy/hold/sell recommendations and forecasts for revenue, EPS and EBITDA for the upcoming fiscal years.
IRIDEX Corporation is a medical technology firm specializing in ophthalmology. They develop and supply advanced therapeutic laser systems, various delivery instruments, and essential consumable tools designed to address vision-threatening ocular conditions. Their product portfolio includes several laser consoles, each tailored for specific eye conditions. The Cyclo G6 system is specifically engineered for glaucoma treatment.
Analyst Consensus
| Strong Buy | 0 |
| Buy | 3 |
| Hold | 1 |
| Sell | 0 |
| Strong Sell | 0 |
| Total analysts | 4 |
| Avg rating (1-5) | 0.75 |
Recent Earnings Surprises
| Date | EPS Actual | EPS Est. | vs Est. |
|---|---|---|---|
| 2026-11-17 | $-0.04 | ||
| 2026-08-18 | $-0.07 | $-0.01 | -600.0% |
| 2026-05-19 | $-0.03 | $-0.07 | +57.1% |
| 2026-03-26 | $-0.01 | $-0.02 | +50.0% |
| 2025-11-11 | $-0.09 | $-0.02 | -350.0% |
| 2025-08-12 | $-0.06 | $-0.09 | +33.3% |
| 2025-05-13 | $-0.10 | $-0.10 | +0.0% |
| 2025-03-27 | $-0.05 | $-0.05 | +0.0% |
Valuation Ratios
| Price / Book | 2.90 |
| EV / EBITDA | -6.71 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $46.2M | $41.6M | $42.6M | $43.4M | $36.3M | $53.9M | $57.0M | $51.9M | $48.7M | $52.7M |
| Cost of Revenue | $25.3M | $26.1M | $25.1M | $25.5M | $20.8M | $31.1M | $31.6M | $30.1M | $29.2M | $33.4M |
| Gross Profit | $20.8M | $15.5M | $17.5M | $17.9M | $15.6M | $22.8M | $25.4M | $21.8M | $19.5M | $19.3M |
| Research & Development | $5.4M | $5.7M | $4.0M | $3.7M | $3.3M | $6.9M | $7.2M | $6.8M | $5.4M | $3.7M |
| Selling, General & Admin | $17.9M | $22.8M | $26.3M | $23.2M | $18.9M | $23.5M | $25.7M | $25.0M | $22.4M | $18.1M |
| Operating Expenses | $23.3M | $28.5M | $30.3M | $26.9M | $22.1M | $30.4M | $32.9M | $31.8M | $27.8M | $21.9M |
| Operating Income | -$2.6M | -$12.9M | -$12.9M | -$9.0M | -$6.6M | -$7.5M | -$7.5M | -$10.0M | -$8.3M | -$2.6M |
| EBITDA | -$1.8M | -$12.2M | -$12.1M | -$8.3M | -$6.1M | -$4.4M | -$6.1M | -$7.4M | -$7.4M | -$2.8M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Pre-tax Income | -$2.7M | -$13.0M | -$12.8M | -$8.8M | -$6.3M | -$5.2M | -$7.5M | -$9.5M | -$8.8M | -$4.4M |
| Income Tax | $9.1M | -$128000 | $37000 | $48000 | $26000 | $40000 | $65000 | $90000 | $68000 | $57000 |
| Net Income | -$11.7M | -$12.9M | -$12.8M | -$8.8M | -$6.3M | -$5.2M | -$7.5M | -$9.6M | -$8.9M | -$4.4M |
| EPS | $-1.15 | $-1.11 | $-1.05 | $-0.64 | $-0.46 | $-0.34 | $-0.47 | $-0.59 | $-0.54 | $-0.26 |
| EPS (Diluted) | $-1.15 | $-1.11 | $-1.05 | $-0.64 | $-0.46 | $-0.34 | $-0.47 | $-0.59 | $-0.54 | $-0.26 |
| Shares Outstanding (Diluted) | $10.2M | $11.6M | $12.2M | $13.7M | $13.8M | $15.4M | $15.9M | $16.1M | $16.4M | $17.2M |
Price
| Price | $0.61 |
| Market Cap | $11M |
| Exchange | NASDAQ |
| Country | US |
Related companies: ADGM · ALUR · ASBP · COCH · HOTH · IINN · NVNO
Explore sector: Healthcare · Medical - Devices
More sections of IRIX: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks